Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Kisspeptin-10 is the shortest bioactive fragment (10 amino acids) of the endogenous neuropeptide kisspeptin, encoded by the KISS1 gene. It acts as an agonist at the KISS1R (GPR54) receptor and stimulates hypothalamic GnRH neurons, driving release of LH and FSH. Kisspeptin is a master switch of puberty and reproduction and is studied in humans, notably by the group of Waljit Dhillo (Imperial College London), in reproductive disorders and in sexual and emotional brain processing. It is not an approved drug.
Researched for
Stimulation of the gonadotropin axis (LH/FSH) in physiological human studiesSexual and emotional brain processing (functional imaging)Reproductive disorders and hypothalamic axis function (research context)
Official status
US: Research only
Kisspeptin-10 is not approved by the FDA as a drug. It is used solely in academic and clinical research and is not intended for human use outside approved studies.
Kisspeptin-10 comprises the ten C-terminal amino acids sufficient for binding to the KISS1R receptor (also GPR54). KISS1R is a G-protein-coupled receptor expressed predominantly on GnRH neurons in the hypothalamus. Activation signals through the Gq/11-phospholipase C pathway to release gonadotropin-releasing hormone (GnRH), which in turn drives the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Kisspeptin signaling is regarded as an indispensable trigger of puberty; inactivating mutations in KISS1R are associated with absent puberty (idiopathic hypogonadotropic hypogonadism). Beyond the reproductive axis, KISS1R expression is described in limbic brain regions, discussed as a possible mechanism for the effects on sexual and emotional processing observed in imaging studies.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · 2 tiers
Human RCT
2
Human trial
2
03
What the studies show
Human trial
Mensch
Jayasena CN. et al. 2015
Intravenous administration of kisspeptin-10 increased secretion of luteinizing hormone (LH), and to a lesser extent FSH, in physiological human studies in healthy men.
What does NOT follow: Small mechanistic studies in selected healthy volunteers; the short isoform acts more briefly and partly less potently than kisspeptin-54. No statement about clinical benefit or use.
Human RCT
Mensch
Comninos AN. et al. 2017
Kisspeptin administration modulated activity of limbic brain regions in response to sexual and emotional stimuli in randomized, placebo-controlled imaging studies (fMRI).
What does NOT follow: Surrogate endpoints (brain activation, connectivity) in small cohorts of healthy men; a direct therapeutic benefit cannot be inferred from this.
Human RCT
Mensch
Mills EG. et al. 2023
In men with hypoactive sexual desire disorder (HSDD), kisspeptin altered sexual brain processing in a randomized controlled trial and was associated with increased penile tumescence versus placebo.
What does NOT follow: Cross-over study with a small sample size and short observation; an exploratory finding requiring larger and longer trials. Not a usage recommendation.
Human trial
Mensch
Endogenous kisspeptin-KISS1R signaling is required for normal onset of puberty; inactivating mutations are associated with absent puberty.
What does NOT follow: Insight from human genetics and basic research on endogenous physiology, not from external administration of kisspeptin-10.
04
Where studies disagree
Open question
Kisspeptin-10 or kisspeptin-54 — which isoform is more suitable?
POSITION A
Kisspeptin-10 acts only briefly due to its short half-life; discussed more for bolus/short-stimulation questions.
POSITION B
Kisspeptin-54 acts longer and is preferred for sustained stimulation.
CURRENT STATE · Both isoforms stimulate gonadotropins; which is more suitable depends on the research question and is assessed differently in the literature.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 0.07 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Intravenous
In most human studies kisspeptin-10 was administered intravenously (bolus or infusion) to study the short duration of action of the isoform in a controlled way.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
There is no approved human use for this substance. What circulates online about amounts and frequency is self-experimentation without a safety net.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Generally good tolerability in the controlled short-term studies
Data come from small, controlled single-dose/short-infusion studies in healthy volunteers; they allow no statement on long-term safety or repeated use.
in den publizierten Studien keine schwerwiegenden Ereignisse berichtet
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Limited evidence on long-term safety
Available human evidence is limited to small, short, controlled studies. There are no robust data on repeated or long-term exposure; kisspeptin-10 is not an approved drug.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Kisspeptin-10 is described in forums for increased libido, fertility and testosterone.
recurring in hormone/fertility discussions
Not supported by studies: Kisspeptin is established in reproductive research — predominantly as a scientific tool for studying the hormone axis, not as a consumer-ready application. Its very short half-life and the absence of controlled user studies run counter to the forum expectations.
11
Legal status by country
Country
Status
Note
Checked
United States
Research only
Kisspeptin-10 is not approved by the FDA as a drug. It is used solely in academic and clinical research and is not intended for human use outside approved studies.
2026-06-07
Germany
Unapproved
No approval by the EMA or BfArM. In Germany kisspeptin-10 is not marketable as a medicinal product and is used only within scientific research.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.